X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABX-002 is a novel, orally administered, potent, and selective thyroid hormone beta agonist, which is investigated for the treatment of major depressive disorder.
Lead Product(s): ABX-002
Therapeutic Area: Psychiatry/Psychology Product Name: ABX-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
ABX-002 is an orally administered, potent, selective thyroid hormone beta (TRβ) agonist that is brain enhanced, demonstrates target engagement in brain regions associated with depression.
Lead Product(s): ABX-002
Therapeutic Area: Psychiatry/Psychology Product Name: ABX-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Autobahn has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma. ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated prodrug conversions.
Lead Product(s): ASP3652,ABX-003
Therapeutic Area: Immunology Product Name: ASP3652
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 11, 2021
Details:
Administration of ABX-002 resulted in potent and on-target responses in preclinical models of AMN and support company's continued advancement of ABX-002 toward clinical evaluation for the treatment of people with this rare and very difficult disease.
Lead Product(s): ABX-002
Therapeutic Area: Genetic Disease Product Name: ABX-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2021
Details:
Autobahn has gained alignment with FDA on the initial Phase 1a/b clinical trial protocol for ABX-002 as a monotherapy treatment for a rare neurological disorder, adrenomyeloneuropathy (AMN).
Lead Product(s): ABX-002
Therapeutic Area: Genetic Disease Product Name: ABX-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Proceeds will be used to advance Autobahn’s lead program candidate, ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS) and adrenomyeloneuropathy (AMN).
Lead Product(s): ABX-002
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $76.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
